Verax Biomedical specializes in platelet bacterial contamination detection in cells and tissues intended for transfusion and transplantation.
Location: United States, Massachusetts, Marlborough
Employees: 11-50
Total raised: $12M
Founded date: 1999
Investors 3
| Date | Name | Website |
| 08.09.2026 | BioVenture... | bioventure... |
| - | KB Partner... | kbpartners... |
| - | LRVHealth | lrvhealth.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.10.2013 | - | $12M | - |
Mentions in press and media 7
| Date | Title | Description |
| 10.10.2013 | Verax Biomedical Closes $12M Funding Round | MARLBOROUGH, MA, Verax Biomedical announced today that it has completed a $12 million financing. >> Click here for more funding data on Verax Biomedical >> To export Verax Biomedical funding data to PDF and Excel, click here... |
| 09.10.2013 | Verax Biomedical Closes $12MM Funding Round | Funding supports ongoing commercialization of Platelet PGD® Test; positions company for significant expansion and market growth in 2014 MARLBOROUGH, Mass.–(BUSINESS WIRE)–October 9, 2013– Signaling its intent to capitalize on the opportunit... |
| 09.10.2013 | Technology to screen blood for bacteria before transfusions raises $12M | Among Verax Biomedical’s investors are Village Ventures and KB Partners. The company points points out that the risk of bacterial contamination in red blood cells is lower than in platelets but it is far higher than the risk of contracting ... |
| 09.10.2013 | Verax Biomedical Completes $12m Financing | Verax Biomedical, a Marlborough, Massachusetts-based developer of rapid tests for detecting bacterial contaminants in blood cells and tissue, completed a $12m financing. The round was led by existing vc investors. The company intends to use... |
| 26.10.2012 | Diagnostics firm with bacteria detection for blood transfusions raising $5 million | Solution/product: Its Pan Genera Detection technology is aimed at detecting bacterial contamination in cells and tissues for blood transfusions and transplantations. Its Platelet PGD Test is the only test approved by the US Food and Drug Ad... |
| - | Technology to screen blood for bacteria before transfusions raises $12M | Each year, about 13.9 million units of red cells or whole blood are transfused in the U.S. Blood transfusions come with some risks, particularly the danger that the recipient will contract a life threatening illness from contaminated blood.... |
| - | Diagnostics firm with bacteria detection for blood transfusions raising $5 million | Company name: Verax Biomedical Industry: Medical devices Location: Worcester, Massachusetts Solution/product: Its Pan Genera Detection technology is aimed at detecting bacterial contamination in cells and tissues for blood transfusions and ... |